These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safinamide (Xadago) for Parkinson's disease. Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. Rodríguez-Jorge F; Beltrán-Corbellini Á; Chico-García JL; Parra-Díaz P; Baena-Álvarez B; Pagonabarraga J; Pérez-Torre P; Pareés I; López-Sendón JL; Martínez-Castrillo JC; Alonso-Cánovas A Parkinsonism Relat Disord; 2022 Apr; 97():73-74. PubMed ID: 35344893 [No Abstract] [Full Text] [Related]
5. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study. Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101 [TBL] [Abstract][Full Text] [Related]
6. Safinamide for the treatment of Parkinson's disease. deSouza RM; Schapira A Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022 [TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Fabbri M; Rosa MM; Abreu D; Ferreira JJ Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. Kurihara K; Mishima T; Fujioka S; Tsuboi Y Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253 [TBL] [Abstract][Full Text] [Related]
9. Safinamide: first global approval. Deeks ED Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099 [TBL] [Abstract][Full Text] [Related]
10. Safinamide: A Review in Parkinson's Disease. Blair HA; Dhillon S CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399 [TBL] [Abstract][Full Text] [Related]
11. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M; Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176 [TBL] [Abstract][Full Text] [Related]
13. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease. Abbruzzese G; Barone P; Lopiano L; Stocchi F Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766 [TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. Jost WH; Kupsch A; Mengs J; Delf M; Bosse D Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650 [TBL] [Abstract][Full Text] [Related]
16. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis. Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R; Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035 [TBL] [Abstract][Full Text] [Related]